Highlights from the ESMO 2021 Congress

Conducted as a virtual event from 16 to 21 September, ESMO 2021 brought together an international community of experts across disciplines.

Once again, this oncology conference’s greatest focus was on large-practice-changing studies of drugs, many of which are already marketed by big biopharma companies.

If you were unable to attend ESMO 2021 or would like to revisit some of the key insights shared at the conference, this Evaluate Vantage article pack provides a roundup of the top trends, data and more, brought to you by our team of award-winning journalists.


Astra finally sees a Wee1 signal

It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.

Colorectal cancer could be Mirati’s golden ticket

Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.

Enhertu sets
a very high bar

A move into the larger second-line breast cancer setting is surely on the way for the AstraZeneca and Daiichi drug.

Keytruda challenges Jemperli and adjuvant melanoma

Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
Look out Agenus, Keytruda is about to put up a roadblock

Merck & Co’s Keytruda is the only anti-PD-(L)1 drug with a cervical cancer label, and it could move from second to first-line use, suggests an abstract on the Keynote-826 study.
Mahogany loses its polish for Macrogenics

Macrogenics is already struggling to justify a role for Margenza in Her2-positive breast cancer, and it seems that gastric tumours will prove no less difficult.
Opdivo’s glimmer of hope in frontline head and neck cancer

The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?

Poziotinib could add first-line string to its bow

Spectrum’s poziotinib keeps throwing up surprises. Late-breaking data presented at ESMO suggests that the project could have broader potential than expected.
The jury remains out on CDK7 inhibition

Clinical data on Carrick’s samuraciclib and Syros’s SY-5609 show that this mechanism remains a work in progress.